Selank + Semax blend news and clinical trials
Also known as: Semax + Selank · Selank/Semax blend · Semax/Selank blend · Selank Semax peptide blend · Russian nootropic stack
Updated 22 sources
9 new studies and 1 regulatory action in the last 12 months, newest first: trial registrations and results, PubMed papers, FDA actions and press coverage that name Selank + Semax blend. Each line links to the primary source.
October 2026
- StudyPubMed[Expert Council resolution: adjunctive pharmacotherapy for hyperkinetic disorders (attention deficit hyperactivity disorder) in children and adolescents] (opens PubMed)
The Expert Council of the National Association of Pediatric Neurologists stratified Cerebrolysin into Group B, representing medications for ADHD with a limited evidence base, to be used only within a multidisciplinary approach.
Zhurnal nevrologii i psikhiatrii imeni S.S. KorsakovaPMID 42910684 - StudyPubMed[Changes in retinal light sensitivity and morphometry during surgical treatment of primary glaucoma with physiotherapeutic stimulation] (opens PubMed)
Researchers assessed the effects of adjunctive physiotherapy after glaucoma surgery in 50 patients. The physiotherapy course, which included the peptide Semax, improved mean deviation in retinal function for up to 6 months post-surgery.
Vestnik oftalmologiiPMID 42885627
June 2026
- StudyPubMed[Effect of a combined physiotherapeutic approach on changes in functional parameters after endovitreal surgery of rhegmatogenous retinal detachment with a favorable anatomical outcome] (opens PubMed)
A study of 42 patients undergoing surgery for retinal detachment found that a combined physiotherapy approach, involving heliox therapy and the peptide Semax, improved visual acuity and microperimetry results compared to using Semax drops alone.
Vestnik oftalmologiiPMID 42366656
May 2026
- StudyPubMedDigitally Guided Hybrid Maxillary Expansion with Supragingival Mandibular Miniplates for Class III Correction in Late Adolescents: A Pilot Clinical Study (opens PubMed)
New paper in Journal of clinical medicine: Digitally Guided Hybrid Maxillary Expansion with Supragingival Mandibular Miniplates for Class III Correction in Late Adolescents: A Pilot Clinical Study.
Journal of clinical medicinePMID 42074872
April 2026
- StudyPubMedTherapeutic peptides in gerontology: mechanisms and applications for healthy aging (opens PubMed)
New review in Frontiers in aging: Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
Frontiers in agingReviewPMID 42021992 - RegulatoryFederal RegisterPharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List (opens Federal Register)
The FDA announced a public advisory committee meeting of the Pharmacy Compounding Advisory Committee to seek input on bulk drug substances nominated for the Section 503A bulk drug substances list.
NoticeFood and Drug Administration2026-07361
January 2026
- StudyPubMedTherapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (opens PubMed)
A review published in the Journal of the American Academy of Orthopaedic Surgeons analyzed the use of therapeutic peptides in orthopaedics. The authors noted that while peptides show promise in preclinical models for tissue regeneration, there is currently a lack of clinical trials.
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviewsReviewPMID 41490200 - StudyPubMedThe Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease (opens PubMed)
Scientists tested the peptide Semax and its derivative in a mouse model of Alzheimer's disease. Both compounds improved cognitive functions and reduced the number of amyloid inclusions in the cortex and hippocampus of the animals.
Acta naturaePMID 41479572
November 2025
- StudyPubMedEffect of ACTH4-10Pro8-Gly9-Pro10 on anti-inflammatory cytokine (IL-4, IL-10, IL-13) expression in acute spinal cord injury models (male Sprague Dawley rats) (opens PubMed)
Investigators administered the peptide Semax intranasally to rats with spinal cord injuries to analyze its anti-inflammatory effects. Treatment increased the expression of anti-inflammatory cytokines IL-4, IL-10, and IL-13 in both mild and severe injury models.
F1000ResearchPMID 41179234
October 2025
- StudyPubMedThe Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons (opens PubMed)
Researchers studied the effect of the peptide Semax on neurons in rat brain slices. The application of 1 μM Semax increased the frequency of spontaneous intracellular calcium fluctuations in hippocampal CA1 pyramidal cells.
Bulletin of experimental biology and medicinePMID 41171324